AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Asthma, Pipeline Review, H2 2019 - Shortness of Breath, Chest Tightness or Pain, Chronic Coughing & Trouble Sleeping - ResearchAndMarkets.com

January 29, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 29, 2020--

The “Asthma - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2019, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 15, 47, 32, 2, 111, 27 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.

Scope:

Reasons to buy

Key Topics Covered:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sos1y3

View source version on businesswire.com:https://www.businesswire.com/news/home/20200129005426/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/29/2020 08:13 AM/DISC: 01/29/2020 08:13 AM

http://www.businesswire.com/news/home/20200129005426/en